Literature DB >> 12771008

Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography.

Rory Hachamovitch1, Sean W Hayes, John D Friedman, Ishac Cohen, Daniel S Berman.   

Abstract

BACKGROUND: The relationship between the amount of inducible ischemia present on stress myocardial perfusion single photon emission computed tomography (myocardial perfusion stress [MPS]) and the presence of a short-term survival benefit with early revascularization versus medical therapy is not clearly defined. METHODS AND
RESULTS: A total of 10 627 consecutive patients who underwent exercise or adenosine MPS and had no prior myocardial infarction or revascularization were followed up (90.6% complete; mean: 1.9+/-0.6 years). Cardiac death occurred in 146 patients (1.4%). Treatment received within 60 days after MPS defined subgroups undergoing revascularization (671 patients, 2.8% mortality) or medical therapy (MT) (9956 patients, 1.3% mortality; P=0.0004). To adjust for nonrandomization of treatment, a propensity score was developed using logistic regression to model the decision to refer to revascularization. This model (chi2=1822, c index=0.94, P<10-7) identified inducible ischemia and anginal symptoms as the most powerful predictors (83%, 6% of overall chi2) and was incorporated into survival models. On the basis of the Cox proportional hazards model predicting cardiac death (chi2=539, P<0.0001), patients undergoing MT demonstrated a survival advantage over patients undergoing revascularization in the setting of no or mild ischemia, whereas patients undergoing revascularization had an increasing survival benefit over patients undergoing MT when moderate to severe ischemia was present. Furthermore, increasing survival benefit for revascularization over MT was noted in higher risk patients (elderly, adenosine stress, and women, especially those with diabetes).
CONCLUSIONS: Revascularization compared with MT had greater survival benefit (absolute and relative) in patients with moderate to large amounts of inducible ischemia. These findings have significant consequences for future approaches to post-single photon emission computed tomography patient management if confirmed by prospective evaluations.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12771008     DOI: 10.1161/01.CIR.0000072790.23090.41

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  400 in total

1.  Diagnostic performance of combined noninvasive coronary angiography and myocardial perfusion imaging using 320 row detector computed tomography: design and implementation of the CORE320 multicenter, multinational diagnostic study.

Authors:  Andrea L Vavere; Gregory G Simon; Richard T George; Carlos E Rochitte; Andrew E Arai; Julie M Miller; Marcello Di Carli; Armin Arbab-Zadeh; Armin A Zadeh; Marc Dewey; Hiroyuki Niinuma; Roger Laham; Frank J Rybicki; Joanne D Schuijf; Narinder Paul; John Hoe; Sachio Kuribyashi; Hajime Sakuma; Cesar Nomura; Tan Swee Yaw; Klaus F Kofoed; Kunihiro Yoshioka; Melvin E Clouse; Jeffrey Brinker; Christopher Cox; Joao A C Lima
Journal:  J Cardiovasc Comput Tomogr       Date:  2011-11-12

2.  Prognostic value of automated vs visual analysis for adenosine stress myocardial perfusion SPECT in patients without prior coronary artery disease: a case-control study.

Authors:  Yuan Xu; Ryo Nakazato; Sean Hayes; Rory Hachamovitch; Victor Y Cheng; Heidi Gransar; Romalisa Miranda-Peats; Mark Hyun; Leslee J Shaw; John Friedman; Guido Germano; Daniel S Berman; Piotr J Slomka
Journal:  J Nucl Cardiol       Date:  2011-09-20       Impact factor: 5.952

3.  Complementary roles of coronary calcium scanning and myocardial perfusion SPECT.

Authors:  Daniel S Berman
Journal:  J Nucl Cardiol       Date:  2004 Jul-Aug       Impact factor: 5.952

Review 4.  Assessing clinical impact of myocardial perfusion studies: ischemia or other prognostic indicators?

Authors:  Todd D Miller; John Wells Askew; Joerg Herrmann
Journal:  Curr Cardiol Rep       Date:  2014-04       Impact factor: 2.931

Review 5.  Assessing the prognostic implications of myocardial perfusion studies: identification of patients at risk vs patients who may benefit from intervention?

Authors:  Paul Cremer; Rory Hachamovitch
Journal:  Curr Cardiol Rep       Date:  2014-04       Impact factor: 2.931

6.  Diagnostic accuracy of gated Tc-99m sestamibi stress myocardial perfusion SPECT with combined supine and prone acquisitions to detect coronary artery disease in obese and nonobese patients.

Authors:  Daniel S Berman; Xingping Kang; Hidetaka Nishina; Piotr J Slomka; Leslee J Shaw; Sean W Hayes; Ishac Cohen; John D Friedman; James Gerlach; Guido Germano
Journal:  J Nucl Cardiol       Date:  2006 Mar-Apr       Impact factor: 5.952

7.  Characteristics and outcomes of revascularized patients with hypertension: an international verapamil SR-trandolapril substudy.

Authors:  Scott J Denardo; Franz H Messerli; Efrain Gaxiola; Juan M Aranda; Rhonda M Cooper-Dehoff; Eileen M Handberg; Yan Gong; Annette Champion; Qian Zhou; Carl J Pepine
Journal:  Hypertension       Date:  2009-02-23       Impact factor: 10.190

Review 8.  Myocardial ischemia is a key factor in the management of stable coronary artery disease.

Authors:  Kohichiro Iwasaki
Journal:  World J Cardiol       Date:  2014-04-26

Review 9.  Nuclear stress testing in elderly patients: a review of its use in the assessment of cardiac risk, particularly in patients undergoing preoperative risk assessment.

Authors:  Amgad N Makaryus; Joseph A Diamond
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

10.  Myocardial perfusion imaging with a solid-state camera: simulation of a very low dose imaging protocol.

Authors:  Ryo Nakazato; Daniel S Berman; Sean W Hayes; Mathews Fish; Richard Padgett; Yuan Xu; Mark Lemley; Rafael Baavour; Nathaniel Roth; Piotr J Slomka
Journal:  J Nucl Med       Date:  2013-01-15       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.